Combination therapy for pulmonary arterial hypertension: still more questions than answers
Open Access
- 1 September 2004
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 24 (3) , 339-340
Abstract
In the past few years, three classes of substances have emerged as effective treatments for PAH: prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors 2. These substances act by different modes of action. Prostanoids replace endogenous prostacyclin, production of which is decreased or absent in the pulmonary vessels of PAH patients 3, 4, and exert vasodilatory and antiproliferative effects predominantly via the intracellular second messenger, cyclic adenosine 5′-monophosphate (cAMP). Endothelin-1 is overexpressed in PAH and causes deleterious effects such as pulmonary vasoconstriction and vascular smooth muscle cell proliferation 5; effects which are blocked by the administration of endothelin receptor antagonists. Phosphodiesterase-5 inhibitors augment the action of endogenous nitric oxide by inhibiting degradation of the second messenger cyclic guanosine 5′-monophosphate (cGMP) 6, thereby causing pulmonary vasodilatation and inhibition of vascular smooth muscle cell proliferation 7. Thus, since all these substances act via different intracellular pathways, combining them may exert synergistic effects.Keywords
This publication has 27 references indexed in Scilit:
- Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2European Respiratory Journal, 2004
- Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoidsEuropean Respiratory Journal, 2003
- Beraprost therapy for pulmonary arterial hypertensionJACC, 2003
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJACC, 2002
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Endothelins and Endothelin Receptor AntagonistsCirculation, 2000
- An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary HypertensionNew England Journal of Medicine, 1992